Argá Medtech Announces First Enrollments in COHERENT-AF IDE Clinical Trial
– Second generation pulsed field ablation system will be evaluated in paroxysmal and persistent atrial fibrillation patients to gain FDA approval –
Excerpt from the Press Release:
LAUSANNE, Switzerland and SAN DIEGO, Sept. 18, 2025 /PRNewswire/ — Argá Medtech, developers of the Coherent Sine-Burst Electroporation™ (CSE™) System, a next-generation pulsed field ablation (PFA) system for treating cardiac arrhythmias, including atrial fibrillation (AF), announced today initial enrollments in the COHERENT-AF clinical trial. COHERENT-AF, a U. S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial is a prospective, non-randomized, trial designed to evaluate the safety and effectiveness of the CSE System in patients with paroxysmal and persistent atrial fibrillation (AF). The COHERENT-AF trial will enroll up to 360 patients across clinical sites in the United States and Europe.
The first patients were treated by Dr. Ante Anic, at KBC Split Hospital, Split, Croatia. Post-procedure all patients were doing well and have subsequently been released from hospital to continue their recovery. Following the procedures Dr. Anic noted that “The flexibility of the CSE platform fills a gap when treating patients beyond pulmonary vein isolation. The single, stylet-driven, multi-configurable ablation catheter easily transitions to deliver linear and focal ablations providing procedural efficiencies when treating both paroxysmal and persistent AF patients and adds an additional layer of safety by eliminating catheter exchanges.”
The CSE system has been used to date in over 100 patients demonstrating greater than 94% lesion durability at 3 months, 92.6% freedom from atrial arrhythmias at 6-months and a 1.0% adverse event rate in Arga Medtech’s initial BURST-AF clinical study.1 “Initiation of COHERENT-AF is a major milestone for Arga Medtech,” said David Neale, CEO of Argá Medtech. “It marks the start of our journey to bring a next generation, safe, fast, and effective ablation treatment to the millions of people affected by cardiac rhythm disorders and atrial fibrillation.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?